The Prognosis and the Role of Adjuvant Chemotherapy for Node-Positive Bladder Cancer Treated with Neoadjuvant Chemotherapy Followed by Surgery
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: This study aims to evaluate the prognosis of pathologically node-positive bladder cancer after neoadjuvant chemotherapy, the role of adjuvant chemotherapy in these patients, and the value of preoperative clinical evaluation for lymph node metastases. Materials and methods: Patients who received neoadjuvant chemotherapy followed by partial/radical cystectomy and had pathologically confirmed lymph node metastases between January 2007 and December 2019 were identified and analyzed. Results: A total of 53 patients were included in the study. The median age was 61 years (range, 34 to 81 years) with males comprising 86.8%. Among the 52 patients with post-neoadjuvant/pre-operative computed tomography results, only 33 patients (63.5%) were considered positive for lymph node metastasis. Sixteen patients (30.2%) received adjuvant chemotherapy (AC group), and 37 patients did not (no AC group). With the median follow-up duration of 67.7 months, the median recurrence-free survival (RFS) and the median overall survival (OS) was 8.5 months and 16.2 months, respectively. The 2-year RFS and OS rates were 23.3% and 34.6%, respectively. RFS and OS did not differ between the AC group and no AC group (median RFS, 8.8 months vs. 6.8 months, p=0.772; median OS, 16.1 months vs. 16.3 months, p=0.479). Thirty-eight patients (71.7%) experienced recurrence. Distant metastases were the dominant pattern of failure in both the AC group (91.7%) and no AC group (76.9%). Conclusion: Patients with lymph node-positive disease after neoadjuvant chemotherapy followed by surgery showed high recurrence rates with limited survival outcomes. Little benefit was observed with the addition of adjuvant chemotherapy.
Abstract
Purpose: This study aims to evaluate the prognosis of pathologically node-positive bladder cancer after neoadjuvant chemotherapy, the role of adjuvant chemotherapy in these patients, and the value of preoperative clinical evaluation for lymph node metastases. Materials and methods: Patients who received neoadjuvant chemotherapy followed by partial/radical cystectomy and had pathologically confirmed lymph node metastases between January 2007 and December 2019 were identified and analyzed. Results: A total of 53 patients were included in the study. The median age was 61 years (range, 34 to 81 years) with males comprising 86.8%. Among the 52 patients with post-neoadjuvant/pre-operative computed tomography results, only 33 patients (63.5%) were considered positive for lymph node metastasis. Sixteen patients (30.2%) received adjuvant chemotherapy (AC group), and 37 patients did not (no AC group). With the median follow-up duration of 67.7 months, the median recurrence-free survival (RFS) and the median overall survival (OS) was 8.5 months and 16.2 months, respectively. The 2-year RFS and OS rates were 23.3% and 34.6%, respectively. RFS and OS did not differ between the AC group and no AC group (median RFS, 8.8 months vs. 6.8 months, p=0.772; median OS, 16.1 months vs. 16.3 months, p=0.479). Thirty-eight patients (71.7%) experienced recurrence. Distant metastases were the dominant pattern of failure in both the AC group (91.7%) and no AC group (76.9%). Conclusion: Patients with lymph node-positive disease after neoadjuvant chemotherapy followed by surgery showed high recurrence rates with limited survival outcomes. Little benefit was observed with the addition of adjuvant chemotherapy.
참고문헌 (30)
- Grossman HB, "Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer", N Engl J Med, 349, pp.859~866 (2003)
- Sui W, "Use of adjuvant chemotherapy in patients with advanced bladder cancer after neoadjuvant chemotherapy", Bladder Cancer, 3, pp.181~189 (2017)
- Herr HW, "Surgical factors influence bladder cancer outcomes : a cooperative group report", J Clin Oncol, 22, pp.2781~2789 (2004)
- Cha EK, "Poor prognosis of bladder cancer patients with occult lymph node metastases treated with neoadjuvant chemotherapy", BJU Int, 122, pp.627~632 (2018)
- Galsky MD, "Effectiveness of adjuvant chemotherapy for locally advanced bladder cancer", J Clin Oncol, 34, pp.825~832 (2016)
- Seisen T, "Adjuvant chemotherapy vs observation for patients with adverse pathologic features at radical cystectomy previously treated with neoadjuvant chemotherapy", JAMA Oncol, 4, pp.225~229 (2018)
- Zargar-Shoshtari K, "Clinical role of additional adjuvant chemotherapy in patients with locally advanced urothelial carcinoma following neoadjuvant chemotherapy and cystectomy", World J Urol, 34, pp.1567~1573 (2016)
- Martinez Chanza N, "Incidence, patterns, and outcomes with adjuvant chemotherapy for residual disease after neoadjuvant chemotherapy in muscle-invasive urinary tract cancers", Eur Urol Oncol, 3, pp.671~679 (2020)
- Hwang EC, "Extended versus standard lymph node dissection for urothelial carcinoma of the bladder in patients undergoing radical cystectomy", Cochrane Database Syst Rev, 5, pp.CD013336~ (2019)
- McMahon CJ, "Lymphatic metastases from pelvic tumors : anatomic classification, characterization, and staging", Radiology, 254, pp.31~46 (2010)
- Amin MB, "AJCC cancer staging manual" (2017), Springer
- Kassouf W, "Outcome of patients with bladder cancer with pN+ disease after preoperative chemotherapy and radical cystectomy", Urology, 73, pp.147~152 (2009)
- Donat SM, "Potential impact of postoperative early complications on the timing of adjuvant chemotherapy in patients undergoing radical cystectomy : a high-volume tertiary cancer center experience", Eur Urol, 55, pp.177~185 (2009)
- Bajorin DF, "First results from the phase 3 CheckMate 274 trial of adjuvant nivolumab vs placebo in patients who underwent radical surgery for high-risk muscle-invasive urothelial carcinoma(MIUC)", J Clin Oncol, 39(6_Suppl), pp.391~ (2021)
- Wright JL, "The association between extent of lymphadenectomy and survival among patients with lymph node metastases undergoing radical cystectomy", Cancer, 112, pp.2401~2408 (2008)
- Jensen JB, "Extended versus limited lymph node dissection in radical cystectomy : impact on recurrence pattern and survival", Int J Urol, 19, pp.39~47 (2012)
- Gschwend JE, "Extended versus limited lymph node dissection in bladder cancer patients undergoing radical cystectomy : survival results from a prospective, randomized trial", Eur Urol, 75, pp.604~611 (2019)
- "S1011 standard or extended pelvic lymphadenectomy in treating patients undergoing surgery for invasive bladder cancer" (2010)[URL]
- Zaghloul MS, "Adjuvant sandwich chemotherapy plus radiotherapy vs adjuvant chemotherapy alone for locally advanced bladder cancer after radical cystectomy : a randomized phase 2 trial", JAMA Surg, 153, pp.e174591~ (2018)
- Iwata T, "The role of adjuvant radiotherapy after surgery for upper and lower urinary tract urothelial carcinoma : A systematic review", Urol Oncol, 37, pp.659~671 (2019)
- Mehrsai A, "A comparison between clinical and pathologic staging in patients with bladder cancer", Urol J, 1, pp.85~89 (2004)
- Husband JE, "Computer tomography and magnetic resonance imaging in the evaluation of bladder cancer", J Belge Radiol, 78, pp.350~355 (1995)
- Horn T, "Evaluation of computed tomography for lymph node staging in bladder cancer prior to radical cystectomy", Urol Int, 96, pp.51~56 (2016)
- Paik ML, "Limitations of computerized tomography in staging invasive bladder cancer before radical cystectomy", J Urol, 163, pp.1693~1696 (2000)
- Thoeny HC, "Metastases in normal-sized pelvic lymph nodes : detection with diffusion-weighted MR imaging", Radiology, 273, pp.125~135 (2014)
- Mir N, "Fusion of high b-value diffusion-weighted and T2-weighted MR images improves identification of lymph nodes in the pelvis", J Med Imaging Radiat Oncol, 54, pp.358~364 (2010)
- Sweeney P, "Is there a therapeutic role for post-chemotherapy retroperitoneal lymph node dissection in metastatic transitional cell carcinoma of the bladder?", J Urol, 169, pp.2113~2117 (2003)
- Otto T, "Impact of surgical resection of bladder cancer metastases refractory to systemic therapy on performance score : a phase II trial", Urology, 57, pp.55~59 (2001)
- Ho PL, "Outcome of patients with clinically node-positive bladder cancer undergoing consolidative surgery after preoperative chemotherapy: The M.D. Anderson Cancer Center Experience", Urol Oncol, 34, pp.59~ (2016)
- Dodd PM, "Outcome of postchemotherapy surgery after treatment with methotrexate, vinblastine, doxorubicin, and cisplatin in patients with unresectable or metastatic transitional cell carcinoma", J Clin Oncol, 17, pp.2546~2552 (1999)